Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

466 results about "Hyperuricemia" patented technology

Hyperuricemia is an abnormally high level of uric acid in the blood. In the pH conditions of body fluid, uric acid exists largely as urate, the ion form. The amount of urate in the body depends on the balance between the amount of purines eaten in food, the amount of urate synthesised within the body (e.g., through cell turnover), and the amount of urate that is excreted in urine or through the gastrointestinal tract. In humans, the upper end of the normal range is 360 µmol/L (6 mg/dL) for women and 400 µmol/L (6.8 mg/dL) for men.

Probiotics plant solid beverage for treating hyperuricemia and gout

InactiveCN110623182Apreserve nutritional valuedisease resistantSkeletal disorderFood ingredient as taste affecting agentFreeze-dryingCelery seeds
The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.
Owner:胡洁

Xanthine oxidase inhibitory peptide capable of improving renal function and application of xanthine oxidase inhibitory peptide

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.
Owner:OCEAN UNIV OF CHINA +1

Xanthine oxidase inhibitory peptide with uric acid reducing activity and application of xanthine oxidase inhibitory peptide

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.
Owner:FIRST INSTITUTE OF OCEANOGRAPHY MNR +1

Application of pediococcus acidilactici

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici. The pediococcus acidilactici TG005 is preserved in the China Center for Type Culture Collection on June 24, 2024, the preservation number is CCTCC NO: M 20241349, and the preservation address is Wuhan University, Wuhan, China. The pediococcus acidilactici TG005 provided by the invention is a multifunctional probiotic strain, is obtained by screening from domestic healthy human excrement samples, and has good application safety and functional adaptability; the strain can reduce the cholesterol level and prevent cardiovascular diseases; uric acid precursor substances are degraded, uric acid generation is reduced, and hyperuricemia and related diseases are prevented; pathogenic bacteria with fusobacterium nucleatum and bacteroides fragilis can be inhibited, and colorectal cancer is prevented; when being used as a probiotic additive for preparing medicines for degrading cholesterol, preventing cardiovascular diseases caused by high cholesterol, preventing hyperuricemia, colorectal cancer and the like, the lactobacillus plantarum has a wide application prospect.
Owner:JIANGXI CHENGGE BIOTECHNOLOGY CO LTD

Composite probiotic metagen for improving hyperuricemia and application of composite probiotic metagen

The invention provides a composite probiotic metagen for improving hyperuricemia and application thereof, the composite probiotic metagen comprises lactobacillus rhamnosus and animal bifidobacterium subsp. Lactis which are subjected to thermal inactivation treatment, the preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) NO: 30878, and the preservation number of the animal bifidobacterium subsp. Lactis is CGMCC NO: 30902. And the composite probiotic metagen comprises thermally inactivated lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. The production cost of the strains is relatively low, and especially in the fermentation process, the used raw materials are relatively economical. Different from many modern medicines, probiotics and metabolites thereof are usually considered to be safe and have small side effects. The composite probiotic metagen is a probiotic subjected to thermal inactivation treatment, which means that viable bacteria are inactivated, the infection risk and the influence on an immune system are reduced, and the inactivated bacterial strain still has the capability of regulating the immune system and is used as a medicine or a health care product for improving hyperuricemia and hyperuricemia.
Owner:SHENZHEN BEICHEN BIOTECH CO LTD

Application of eupatorium chinense extract in preparation of medicine for treating gout

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.
Owner:CHINA THREE GORGES UNIV

Composition containing dotenorad and xanthinase inhibitor as well as preparation method and application of composition

The invention provides a composition containing dotenorad and a xanthinase inhibitor as well as a preparation method and application of the composition, and belongs to the technical field of pharmacy. The composition provided by the invention comprises dotenorad, a xanthinase inhibitor and at least one pharmaceutically acceptable additive. The composition prepared by the invention has good stability and can be used for clinically treating gout and hyperuricemia.
Owner:FUJIAN ZERUI PHARM CO LTD

Fungus extract for effectively regulating uric acid metabolism and relieving inflammation and application of fungus extract in reducing uric acid

The invention discloses a fungus extract capable of effectively regulating uric acid metabolism and relieving inflammation as well as a preparation method and application of the fungus extract, and belongs to the technical field of deep processing of edible fungi. Schizophyllumcommuneh and poplar phellinus sporocarp are mixed and extracted, and the prepared fungus extract can effectively inhibit activity of xanthine oxidase in serum and liver of mice, reduce content of uric acid, creatinine, urea nitrogen and the like in serum and promote excretion of uric acid, creatinine, urea nitrogen and the like in urine; meanwhile, the content of inflammatory markers such as IL-6 and TNF-alpha in mouse serum can be effectively reduced, inflammatory infiltration of liver and kidney cells is relieved, and the problem that an existing edible mushroom extract is not ideal in treatment effect on hyperuricemia is solved.
Owner:FARM PROD PROCESSING & NUCLEAR AGRI TECH INST HUBEI ACAD OF AGRI SCI

Abdominal distention hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.
Owner:OCEAN UNIV OF CHINA

Lactobacillus fermentum as well as compound preparation and application thereof

The invention provides lactobacillus fermentum as well as a compound preparation and application thereof, and relates to the technical field of microorganisms. Compared with a strain in the prior art, the lactobacillus fermentum HXJS4-1 disclosed by the invention has a better effect in the aspect of nucleoside degradation and can realize rapid nucleoside degradation. In addition, the compound has a stronger inhibition effect on xanthine oxidase, and the activity of the xanthine oxidase is effectively reduced. In mouse experiments, the strain also has an obvious uric acid reducing effect, also has a certain anti-inflammatory effect, can be used in the prevention and treatment process of hyperuricemia and gout, and provides a new probiotic or drug material for the treatment of hyperuricemia and gout. In addition, eating of the strain has no obvious influence on indexes of a sample body, and it is proved that the strain has the characteristic of high safety and can be widely applied to the fields of medicine and food.
Owner:BLOOMATURE BIOTECHNOLOGY CO LTD

Application of sea cucumber intestine polysaccharide in preparation of uric acid reducing medicine

The invention relates to an application of sea cucumber intestine polysaccharide in preparation of uric acid lowering drugs. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.
Owner:BOHAI UNIV

Traditional Chinese medicine compound and preparation for reducing blood uric acid and relieving pain and preparation method thereof

The invention discloses a traditional Chinese medicine compound and preparation for reducing blood uric acid and relieving pain and a preparation method of the traditional Chinese medicine compound, belongs to the technical field of traditional Chinese medicine compounds, and solves the technical problem that at present, a medicine which does not have side effects and is used for treating hyperuricemia is lacked. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-30 parts of cortex phellodendri, 5-20 parts of rhizoma coptidis, 15-30 parts of rhizoma atractylodis, 20-40 parts of semen coicis, 10-30 parts of radix cyathulae, 10-30 parts of pawpaw, 3-5 parts of fried fructus evodiae, 15-50 parts of radix astragali, 5-15 parts of The traditional Chinese medicine composition has the effects of reducing blood uric acid, resisting inflammation and relieving pain, is reasonable in compatibility, complements each other and has a synergistic effect, and the effects of reducing blood uric acid, resisting inflammation and relieving pain are increased.
Owner:TEACHING HOSPITAL OF CHENGDU UNIV OF T C M

Formulations and doses of pegylated uricase

Provided herein are methods and compositions and kits related to uricase compositions and / or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
Owner:CARTESIAN THERAPEUTICS INC

Application of galangal polysaccharide in preparation of preparation for improving intestinal flora imbalance

The invention belongs to the technical field of biological medicine, and relates to application of galangal polysaccharide in preparation of a preparation for improving intestinal flora imbalance. The galangal polysaccharide provided by the invention can effectively improve the alteration of intestinal flora, especially improve the alteration of intestinal flora induced by hyperuricemia, the hyperuricemia can cause intestinal barrier injury, then the intestinal flora is translocated to induce the alteration of the intestinal flora, and the galangal polysaccharide can up-regulate Occludin and ZO-1, repair the intestinal barrier injury and improve the integrity of the intestinal tract; after the action of the galangal polysaccharide, the influence on the intra-group diversity Beta diversity of the flora is large, the flora structure deviation caused by hypeluricemia can be reversed, and the intestinal flora structure deviation can be relieved. The galangal polysaccharide provided by the invention is a potential novel prebiotic, has an excellent effect in improving intestinal flora imbalance, and has a good application prospect.
Owner:GUANGDONG OCEAN UNIVERSITY

Lactobacillus composition and use thereof

A lactobacillus composition and the use thereof in hyperuricemia, relating to the field of microorganisms. The composition comprises Lactobacillus gasseri BDUP, Lactobacillus fermentum B1B26 and Lactobacillus agilis B13T4. The lactobacillus composition can significantly inhibit the activity of xanthine oxidase XOD in vitro, and, as proved by in-vivo experiments, said probiotic composition can also reduce the content of uric acid in Danio rerio having high uric acid levels and in hyperuricemia model mice and reduce the level of inflammatory factors in mice with hyperuricemia. In addition, the composition has effects obviously superior to that of a single strain and therefore has good development and utilization prospects for treating or preventing and relieving hyperuricemia.
Owner:BEIJING QUANTIHEALTH TECH CO LTD

Application of lactobacillus mucilaginosus TG017 in medicine for preventing and treating hyperuricemia and complications of hyperuricemia

The invention provides a strain of fermentation lactobacillus mucus TG017, and the strain of fermentation lactobacillus mucus TG017 has the effects of reducing uric acid, purine and adenosine. The lactobacillus fermentum is lactobacillus fermentum TG017, is preserved in the China Center for Type Culture Collection on April 10, 2023, has the preservation number of CCTCC NO: M 2023513, and is located in the preservation center of Wuhan University in Hubei China, and the preservation number of the lactobacillus fermentum TG017 is CCTCC NO: M 2023513. The invention further relates to the use of the Lactobacillus mucilaginosus TG017 strain.
Owner:XIAMEN TREATGUT BIOTECHNOLOGY CO LTD

Lentinus edodes peptide prepared based on Maillard reaction and application of lentinus edodes peptide in preparation of products with effects of reducing blood pressure, blood sugar, blood fat and uric acid and antioxidant activity

The invention belongs to the technical field of protein peptide preparation, and particularly relates to mushroom peptide prepared based on Maillard reaction and application of the mushroom peptide to preparation of products with the effects of reducing blood pressure, blood sugar, blood fat and uric acid and antioxidant activity. The mushroom peptide disclosed by the invention has the effects of remarkably reducing blood pressure, blood sugar, blood fat and uric acid and resisting oxidation, and can be used as an auxiliary therapeutic agent or functional food for four high diseases such as hypertension, hyperlipidemia, diabetes mellitus and hyperuricemia and oxidative stress related diseases.
Owner:SHANGHAI ACAD OF AGRI SCI

Quercetin-containing composition for reducing uric acid and improving gout and application of quercetin-containing composition

The invention relates to the technical field of gout treatment, in particular to a quercetin-containing composition for reducing uric acid and improving gout and application of the quercetin-containing composition, and the quercetin-containing composition comprises quercetin or pharmaceutically acceptable salt of the quercetin or a composition containing the quercetin or the pharmaceutically acceptable salt of the quercetin. The quercetin, the pharmaceutically acceptable salt of the quercetin or the composition containing the quercetin or the pharmaceutically acceptable salt of the quercetin and a pharmaceutically acceptable carrier are prepared into a pharmaceutically acceptable dosage form, and the composition containing the quercetin or the pharmaceutically acceptable salt of the quercetin and the pharmaceutically acceptable carrier are prepared into a pharmaceutically acceptable dosage form. Growth of lactobacillus avium CML180 is remarkably promoted through quercetin in a dose-dependent mode, hydrophobicity of the lactobacillus avium CML180 and the common aggregation capacity of the lactobacillus avium CML180 and clostridium perfringens are improved, adhesion of the lactobacillus avium CML180 and intestinal epithelial cells Caco-2 is promoted, hyperuricemia is remarkably relieved through the lactobacillus avium CML180, and the lactobacillus avium CML180 can be used as a medicine for treating hyperuricemia. The generation of liver uric acid is reduced and the excretion of kidney uric acid is increased, so that the gout is improved.
Owner:JIANGMEN SHENGKANGYAN BIOTECHNOLOGY CO LTD

A method for establishing a hyperuricemia prediction model using machine learning algorithms

The present invention provides a method for establishing a hyperuricemia prediction model using a machine learning algorithm, which belongs to the field of health assessment technology. The embodiment of the present invention uses a UKBB cohort based on a large population as training, and uses an internal test set and a dataset of healthy physical examinees from Southern Hospital as an external test set to establish and verify a reliable and practical stacked multimodal machine learning model trained based on genetic and clinical data, which is used to timely identify HUA phenotypes and early predict gout and metabolic-related outcome risks. The model has excellent performance, exceeding each single machine learning model, and shows satisfactory efficacy. The ISHUA marker can quantify gout risk and metabolic-related results at an early stage, can provide active guidance for daily health examinations and the management of risk factors, and provide valuable information support for clinicians to appropriately manage HUA risk factors after routine health screening.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Hexapeptide TE6 with xanthine oxidase inhibitory activity and preparation method and application thereof

The invention discloses a hexapeptide TE6 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide TE6 is TIATVE, and the hexapeptide TE6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide TE6 is identified from a solieria cavaleriei proteolysis solution and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 44.74%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; 0.05), which is stronger in xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.
Owner:YANTAI INST OF COASTAL ZONE RES CHINESE ACAD OF SCI +1

Strain with uric acid lowering and growth-dependent uric acid properties

The invention relates to the technical field of biology, and particularly discloses a strain with a uric acid reducing characteristic and a growth-dependent uric acid characteristic, and the microbial preservation number of the strain is GDMCC No.65914. The uric acid reducing strain is screened from pickles by a transparent ring method, the 16S rRNA gene sequence of the uric acid reducing strain is studied, a resource library of the uric acid reducing strain is expanded, resources are provided for research and development of uric acid reducing drugs in the clinical field, non-target strains are effectively removed through a dual specific screening mechanism of uric acid dependent growth verification and liquid fermentation induced uric acid reduction, and the yield of the uric acid reducing strains is increased. The uric acid reduction and uric acid dependence function stability and metabolic specificity of the screened strain are ensured, the high uric acid reduction strain obtained through screening can be directly used for developing a novel microecological preparation or a uric acid reduction preparation, and compared with traditional chemical drugs, the high uric acid reduction strain has the advantages of being high in safety, good in biocompatibility and small in side effect; high-quality strain resources are provided for biological treatment of hyperuricemia and gout and development of uric acid detection reagents.
Owner:LIANJIANG PEOPLES HOSPITAL

New application and method of asiaticoside

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.
Owner:HAINAN HAIZHIGE INVESTMENT CO LTD

Application of antarctic red pigment in preparation of drugs for treatment and prevention of hyperuricem

The present disclosure relates to an application of Antarctic red pigment in a preparation of drugs for treatment and prevention of hyperuricemia, which belongs to the field of biomedicine. The present disclosure studies a fermentation product of existing fungi Geomycos sp. wnf-18C or Geomycos sp. wnf-15A, and finds that the Antarctic red pigment produced by the fermentation product has good therapeutic effects on hyperuricemia induced by high purines. Thus, this pigment has application value in the preparation of drugs for hyperuricemia induced by high purine.
Owner:LINYI UNIVERSITY

Papaya and lily drink for preventing and treating gout and hyperuricemia and preparation method thereof

InactiveCN119033050ASafe and effective for everyday useno security concernsPharmaceutical delivery mechanismSkeletal disorderCichoriumCoix
The invention relates to the technical field of health-care foods and preparation methods, and particularly discloses a papaya and lily drink for preventing and treating gout and hyperuricemia. The papaya and lily drink is prepared from the following raw materials by gram: 6-8 g of agkistrodon halys, 9-12 g of zaocys dhumnade, 6-8 g of psyllium husk, 10-30 g of celery and 10-15 g of purslane. The traditional Chinese medicine is prepared from 5-10 g of pawpaw, 3-6 g of mulberry, 5-10 g of cape jasmine, 3-7 g of chicory, 7-10 g of radix puerariae, 3-10 g of coix seeds, 5-10 g of towel gourd, 10-30 g of corn stigma, 5-8 g of lily, 30-60 g of rhizoma smilacis glabrae, 30-60 g of sunflower disc, 5-10 g of exocarpium benincasae and According to the preparation method of the papaya and lily beverage capable of preventing and treating gout and hyperuricemia, all the material components of the beverage prepared by the method belong to medicinal and edible foods in a list published by the national health and health committee of both medicines and foods, and the beverage is safe and effective in daily use and has no safety problem; the traditional Chinese medicine composition has the effects of raising qi, nourishing vitality, consolidating basis, regulating the balance of internal organs, preventing yin deficiency, qi deficiency, yin and qi-yin deficiency, effectively eliminating and preventing uric acid turbid toxin, effectively relieving gout symptoms and improving joint functions.
Owner:王稳定

Targeted prebiotic plant extraction dietary powder for relieving hypeluricemia and preparation technology of targeted prebiotic plant extraction dietary powder

The invention discloses targeted prebiotic plant extraction dietary powder for relieving hyperuricemia and a preparation technology of the targeted prebiotic plant extraction dietary powder, and belongs to the technical field of dietary powder.In a formula of the targeted prebiotic plant extraction dietary powder for relieving hyperuricemia, as a patented bacterial strain, the bacillus coagulans MKSWC01 can directly act on the intestinal tract environment, uric acid precursor substances generated by purine metabolism are degraded in a targeted mode, and generation of uric acid is reduced from the source; the chicory root superfine powder and the mulberry leaf DNJ extract respectively activate kidney excretion protein, inhibit the activity of glycosidase, accelerate discharge of uric acid through urine and block the path of conversion from fructose metabolism to uric acid; the celery seed flavone and the smilax glabra polysaccharide further play an anti-inflammatory role, the deposition risk of urate crystals at joints is reduced, and potential inflammatory response caused by hyperuricemia is relieved. Meanwhile, the resistant dextrin and the xylooligosaccharide serve as prebiotics, nutrients are provided for probiotics to support planting of the probiotics, the overall metabolic environment can be improved by adjusting intestinal flora balance, the pathological link of hyperuricemia is comprehensively covered, and the relieving effect is improved.
Owner:CHANGSHA KANGJIN FUCUI TECHNOLOGY CO LTD

Lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of lactobacillus rhamnosus YYSJ019 strain

PendingCN120505235ABacteriaMetabolism disorderFat mouseHuman gastrointestinal tract
The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.
Owner:JIANGSU YIERSHIJIA HEALTH TECHNOLOGY CO LTD

Lactobacillus mucilaginosus and application thereof in preparation of uric acid reducing preparation

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.
Owner:SOUTH CHINA UNIV OF TECH +1

Application of quercetagetin in preparation of medicine for preventing hyperuricemia and / or hyperuricemia-related diseases

The invention relates to the field of biological medicine, in particular to application of quercetagetin in preparation of medicine for preventing hyperuricemia and / or hyperuricemia related diseases. The invention discovers that quercetagetin has a prevention or improvement effect on hyperuricemia and related diseases for the first time. The result of the specific embodiment of the invention shows that the quercetagetin has a good uric acid reducing effect, obviously reduces the activity of uric acid generation participating enzyme, regulates the expression of uric acid transporter mRNA, improves liver injury and kidney injury caused by hyperuricemia, can prevent or relieve hyperuricemia or hyperuricemia-related diseases, and has a good application prospect. The composition can be used for preparing oral tablets and effervescent tablets.
Owner:HEBEI AGRICULTURAL UNIV.